MicroVention | Terumo™

Terumo Website
  • Home

    • Aneurysm Therapy
    • Ischemic Stroke and Carotid Artery Disease
    • Neurovascular Malformations
    • Access Product Solutions
  • Products

    • About Us
    • Executive Team
    • News
    • Events
    • Compliance
    • Overview
    • Job Openings
  • Contact

  • Clinical Education
  • Glossary
  • MV Associates
  • Terumo Group
  • Press Resources
  • Aneurysm Therapy

    Aneurysm Therapy

  • Ischemic Stroke and Carotid Artery Disease

    Ischemic Stroke and Carotid Artery Disease

  • Neurovascular Malformation

    Neurovascular Malformations

  • Access Product Solutions

    Access Product Solutions

  • Home

News & Press

Sep 29, 2022

MicroVention Celebrates 25 Years in Neuroendovascular Technologies that Improve Patient Lives

MicroVention, Inc., a global neurovascular company and a wholly owned subsidiary of Terumo Corporation, celebrates its 25-year anniversary on September 29, 2022. Founded in 1997 by a handful of Associates in a small facility in Southern California, MicroVention is now a worldwide community with over 3,000 Associates and distributors worldwide, operating in over 70 countries with offices across the United States, Europe, Asia, and Costa Rica.

All Types
All Types Articles HR Press Releases
2020
All Years 2010 2012 2013 2015 2016 2017 2018 2019 2020 2021 2022

Dec 23, 2020

MicroVention, Inc. Files Trade Secret Lawsuit Against Balt USA, LLC

MicroVention, Inc., a U.S. based subsidiary of Terumo and leading global neurovascular company, announced today the filing of a second lawsuit against Balt USA, LLC and four former employees for trade secret misappropriation.

Sep 22, 2020

MicroVention-Terumo Announces New Leadership

The Company Appoints New President and CEO

Apr 21, 2020

Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide

Contributions include USD 1 million to the COVID-19 Solidarity Response Fund for WHO

Mar 27, 2020

MicroVention's Response to COVID-19

MicroVention has been closely following the daily developments and guidelines surrounding COVID-19, and our commitment remains true as we adjust to the current circumstances that all of us are facing during this challenging time.

Mar 13, 2020

MicroVention Expands Worldwide Innovation Center

Two years after MicroVention, Inc. relocated their Worldwide Innovation Center to 35 Enterprise, the neurovascular company is expanding within the Summit Office Campus to accommodate for their rapid growth.

Jan 08, 2020

MicroVention Announces FDA Premarket Approval of a New Flow Diverter for the Treatment of Brain Aneurysms

MicroVention, Inc., a U.S. based subsidiary of Terumo and a global neurovascular company announced the FDA Premarket Approval (PMA) for the FRED® (Flow Re-Direction Endoluminal Device) device for the treatment of brain aneurysms.

    • Aneurysm Therapy
    • Ischemic Stroke and Carotid Artery Disease
    • Neurovascular Malformations
    • Access Product Solutions
  • Products

    • About Us
    • Executive Team
    • News
    • Events
    • Compliance
    • Overview
    • Job Openings
  • Contact

  • Clinical Education
  • Glossary
  • MV Associates
  • Terumo Group
  • Press Resources
Europe, Middle East & Africa

©2023 MicroVention Inc.

Privacy Statement

For Suppliers

Terms of Use

Ordering Info Terms & Conditions

Made inHAUSHAUS is a creative design agency based in Los Angeles, California